New pill combo aims to extend life in tough bile duct cancer
NCT ID NCT06622057
First seen Apr 19, 2026 · Last updated May 05, 2026 · Updated 4 times
Summary
This study tests whether adding a new drug (D07001) to standard chemotherapy (capecitabine) helps people with advanced bile duct cancer live longer. It is for patients whose cancer has stopped responding to earlier treatments. About 195 adults will receive either D07001 or a placebo, plus capecitabine, and be followed for survival and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER (BTC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, 807, Taiwan
Contact
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.